NCT04034927: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 61 taking part
- Started
- 4 Dec 2019
- Primary completion
- 31 Jul 2021
- Arms
- Arm II (olaparib, tremelimumab)
- Results
- Posted on the registry
- 29 Jul 2019: Trial registered
- 4 Dec 2019: Trial started
- 13 Oct 2023: Trial results posted